TY - JOUR
T1 - Natural product mogrol attenuates bleomycin-induced pulmonary fibrosis development through promoting AMPK activation
AU - Liu, Bei
AU - Yang, Jinyu
AU - Hao, Jiatong
AU - Xie, Haifeng
AU - Shimizu, Kuniyoshi
AU - Li, Renshi
AU - Zhang, Chaofeng
N1 - Funding Information:
We would like to thank the National Natural Science Foundation (81773982, 81573553 for Chaofeng Zhang), Youth Academic leaders of the Qinglan Project in Jiangsu province (to Chaofeng Zhang) and “Double First-Class” University project (CPU2018GF06).
Publisher Copyright:
© 2020 The Author(s)
PY - 2021/2
Y1 - 2021/2
N2 - Pulmonary fibrosis is a chronic and aggresitive interstitial lung disease. We evaluated the anti-fibrotic effect of mogrol isolated from Siratia grosvenorii against pulmonary fibrosis and the underlying mechanism. In vitro, mogrol (10 µM) show anti-fibrotic effects by suppressing TGF-β1-induced the epithelial mesenchymal transition of alveolar epithelial cells and myofibroblasts trans-differentiation. Then, mogrol was given after intratracheal instillation of bleomycin in mice. Results showed that mogrol treatments (10 mg/kg/d) improved characteristic changes in histopathology, inflammation infiltration and collagen deposition in lung tissues, and that mogrol significantly inhibited TGF-β1-Smad2/3 pathway, restored NOX4 abnormal expression but promoted AMPK phosphorylation. Further research identified that co-treatment with AMPK inhibitor, significantly blocked the anti-fibrotic properties of mogrol, suggesting that the protective effect of mogrol may be attributed to activated AMPK with consequent reduction in inflammatory, fibrosis and oxidative stress. Overall, Siratia grosvenorii effectively protects against lung fibrosis via AMPK activation and amelioration of TGF-β1 signalling pathway.
AB - Pulmonary fibrosis is a chronic and aggresitive interstitial lung disease. We evaluated the anti-fibrotic effect of mogrol isolated from Siratia grosvenorii against pulmonary fibrosis and the underlying mechanism. In vitro, mogrol (10 µM) show anti-fibrotic effects by suppressing TGF-β1-induced the epithelial mesenchymal transition of alveolar epithelial cells and myofibroblasts trans-differentiation. Then, mogrol was given after intratracheal instillation of bleomycin in mice. Results showed that mogrol treatments (10 mg/kg/d) improved characteristic changes in histopathology, inflammation infiltration and collagen deposition in lung tissues, and that mogrol significantly inhibited TGF-β1-Smad2/3 pathway, restored NOX4 abnormal expression but promoted AMPK phosphorylation. Further research identified that co-treatment with AMPK inhibitor, significantly blocked the anti-fibrotic properties of mogrol, suggesting that the protective effect of mogrol may be attributed to activated AMPK with consequent reduction in inflammatory, fibrosis and oxidative stress. Overall, Siratia grosvenorii effectively protects against lung fibrosis via AMPK activation and amelioration of TGF-β1 signalling pathway.
UR - http://www.scopus.com/inward/record.url?scp=85098593958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098593958&partnerID=8YFLogxK
U2 - 10.1016/j.jff.2020.104280
DO - 10.1016/j.jff.2020.104280
M3 - Article
AN - SCOPUS:85098593958
SN - 1756-4646
VL - 77
JO - Journal of Functional Foods
JF - Journal of Functional Foods
M1 - 104280
ER -